72 related articles for article (PubMed ID: 2459727)
21. [Cultivation of the transmissible gastroenteritis virus in a continuous cell line].
Belopopska P; Motovski A
Vet Med Nauki; 1984; 21(6):11-7. PubMed ID: 6093344
[TBL] [Abstract][Full Text] [Related]
22. Studies on new attenuated strains of type III live poliomyelitis vaccine. I. Development of a new type III attenuated poliovirus.
Chin Med J (Engl); 1980 Sep; 93(9):583-90. PubMed ID: 6253236
[No Abstract] [Full Text] [Related]
23. A rapid plaque method using vertical tube cultures for titration of viruses and neutralizing antibodies.
Wallis C; Parks W; Sakurada N; Melnick JL
Bull World Health Organ; 1965; 33(6):795-801. PubMed ID: 5295403
[TBL] [Abstract][Full Text] [Related]
24. Potency testing of killed polio vaccine in rats.
van Steenis G; van Wezel AL; Sekhuis VM
Dev Biol Stand; 1981; 47():119-28. PubMed ID: 6262142
[TBL] [Abstract][Full Text] [Related]
25. Tissue culture of viruses (author's transl).
Can J Med Technol; 1974 Jun; 36(3):231 passim. PubMed ID: 4368290
[No Abstract] [Full Text] [Related]
26. The use of a differential fluorescent staining method to detect bacteriuria.
Ciancaglini E; Fazii P; Sforza GR
Clin Lab; 2004; 50(11-12):685-8. PubMed ID: 15575310
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial of concentrated inactivated polio vaccine in a simplified immunization program.
Fillastre C; Emmou C; Meyran M; Schlumberger M; Guérin N
Dev Biol Stand; 1981; 47():207-13. PubMed ID: 6262148
[TBL] [Abstract][Full Text] [Related]
28. Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccines.
van der Gun J; Akkermans A; Hendriksen C; van de Donk H
Dev Biol Stand; 1996; 86():199-206. PubMed ID: 8785949
[TBL] [Abstract][Full Text] [Related]
29. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line.
Montagnon BJ
Dev Biol Stand; 1989; 70():27-47. PubMed ID: 2759353
[TBL] [Abstract][Full Text] [Related]
30. [Thermostability and immunogenicity of trivalent oral poliovirus vaccine produced by different countries].
Kong J
Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):151-4. PubMed ID: 8221837
[TBL] [Abstract][Full Text] [Related]
31. Polio control after certification: major issues outstanding.
Fine PE; Oblapenko G; Sutter RW
Bull World Health Organ; 2004 Jan; 82(1):47-52. PubMed ID: 15106300
[TBL] [Abstract][Full Text] [Related]
32. Standardization of safety and potency tests of vaccines against poliomyelitis.
Elisberg BL
Rev Infect Dis; 1984; 6 Suppl 2():S519-22. PubMed ID: 6330850
[No Abstract] [Full Text] [Related]
33. A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines.
Wood DJ; Heath AB
Biologicals; 1995 Dec; 23(4):301-11. PubMed ID: 8825859
[TBL] [Abstract][Full Text] [Related]
34. Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay.
Schalk JA; de Vries CG; Jongen PM
Biologicals; 2005 Jun; 33(2):71-9. PubMed ID: 15939284
[TBL] [Abstract][Full Text] [Related]
35. Focus assay for varicella-zoster virus in human embryo cells stained with immunoperoxidase method.
Schmidtmayerová H; Mayer V; Zachar V
Acta Virol; 1986 Nov; 30(6):468-74. PubMed ID: 2881466
[TBL] [Abstract][Full Text] [Related]
36. The propagation of avian viruses in a continuous cell line (QT35) of Japanese quail origin.
Cowen BS; Braune MO
Avian Dis; 1988; 32(2):282-97. PubMed ID: 3135794
[TBL] [Abstract][Full Text] [Related]
37. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
Furesz J; Contreras G
Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
[TBL] [Abstract][Full Text] [Related]
38. Cell substrate for killed poliovaccine production.
Beale AJ
Dev Biol Stand; 1981; 47():19-23. PubMed ID: 6262147
[TBL] [Abstract][Full Text] [Related]
39. Persistent infection of human erythroblastoid cells by poliovirus.
Lloyd RE; Bovee M
Virology; 1993 May; 194(1):200-9. PubMed ID: 8386873
[TBL] [Abstract][Full Text] [Related]
40. WHO recommendation on potential use of new poliomyelitis vaccines.
Ghendon Y
Dev Biol Stand; 1993; 78():133-7; discussion 138-9. PubMed ID: 8388823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
